Key US Panel to Decide on Changing Newborn Hepatitis B Vaccine Advisory

Following a postponement and an unusually contentious gathering, a federal vaccine advisory panel was set to cast ballots on Friday on whether to change the longstanding recommendation that all newborns be inoculated against hepatitis B.

Heated Debate and a Deferred Vote

The initial day of the meeting on Thursday was characterized by heated debate over restricting access to the hepatitis B vaccine for infants and a resolution to postpone the decision by a day to provide committee members extra time to examine the language. The panel, which counsels the Centers for Disease Control and Prevention on immunization practices, had put off the vote twice in the past.

“Is there any definitive data of injury of giving this immunization before 30 days? Or is this speculation?” asked one adviser.

In response, another attendee stated, “There is inadequate data about the long-term risk.”

Current Guidelines and Possible Consequences

The injection is presently advised for every newborn within 24 hours of birth to prevent infection of hepatitis B, which can lead to major damage to the liver. It has been given to over a billion individuals for over thirty years.

The Atlanta conference provided no new evidence of injuries resulting from the vaccine. Authorities state any alteration to the present hepatitis B vaccine regimen could have major and extensive repercussions for pediatric well-being in the United States.

Panel Composition and Recent Changes

The consultative group can only provide advice to the leader of the CDC. The committee's composition has seen shifts this week, with the announcement that the committee’s most recent chair would leave for an agency job and be succeeded by a cardiac doctor who has been skeptical about other vaccines.

The committee includes multiple immunization doubters who align with a desire to overhaul – and perhaps, in some cases, eliminate – traditional vaccine advisories.